RRML - Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients?
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2016): 55%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- October 2020 -
 
Romanian Review of Laboratory ... 17
High frequency of BRCA recurre... 16
Metabolomic biomarkers of poly... 13
Antibacterial and antitumor ac... 12
Troubleshootings in RNA extrac... 12
Evaluation of oxidative stress... 10
The association of anthropomet... 10
Carbapenemase Producing Entero... 9
Characterization of antibiotic... 9
Comparative Evaluation of RNAl... 9

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 19(4)/2011
XML
TXT

Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients?

Rodica Bălaşa, Adina Huţanu, Z. Bajko, Camelia Feier, I. Pascu


Abstract:

Background. The IL-17 is a proinflammatory cytokine that plays an important role in the pathogenesis of multiple sclerosis (MS). Interferon-β (IFN-β) is the major immunomodulatory treatment for relapsing remitting MS (RRMS). Up to two thirds of patients respond to treatment. Criteria to classify patients into responders and non-responders to IFN-β therapy are usually applied after 1 or 2 years follow-up. Objective. To detect the level of serum IL-17A in MS patients treated with IFN-β and find if it plays a role in MS patients’ response to IFN-β. Material and methods. 150 patients with MS (mean age: 41.8±9.2; mean EDSS: 2.8±1.87; 71.3% RRMS, 28.7% SPMS), who had at least 18 months of IFN-β treatment, underwent a serological IL-17A test. IL-17A was tested using ELISA-indirect method, values over 1.6pg were pathological. Patients had at least 30 days without steroids. For each patient, the following were recorded: epidemiological, clinical and treatment features (early vs. late treatment, responder vs. nonresponder, duration of treatment). Mann-Whitney test and Spearmann correlation was used, p values of ≤0.05 were significant. Results. 27 patients (18%) had titers of IL-17 above 1.6pg/ml, mean 3.38 (±13.5). We found correlations between the IL-17A titer and both number of MS relapses (p<0.05) and EDSS (p=0.05). In nonresponders the titer of IL-17 was significantly higher (p=0.03). None of the other parameters correlated. Conclusions. High serum IL-17 concentration in MS treated patients plays a role in nonresponsiveness to IFN-β therapy. Serum IL-17 might be a sensitive biomarker to be used but it must be correlated with other markers for disease activity or response to treatment.

Keywords: multiple sclerosis,interleukine 17,interferon beta

 
  PDF Download full text PDF
(265 KB)
     
 
How to cite
Bălaşa R, Huţanu A, Bajko Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients?. Rev Romana Med Lab. 2011;19(4):381-9